7,515.14

-34.80

-0.46%

52,220.17

-169.58

-0.32%

25,035.47

-217.67

-0.86%

2,818.58

-22.23

-0.78%

4.9830

+0.1190

+2.45%

19.81

-0.11

-0.55%

4,043.50

-71.00

-1.73%

73,619.66

-1,140.20

-1.53%

Crude Oil Dec 26

86.48

-0.37

-0.43%

US Private Equity

10,850.15

0.00

0.00%

Copenhagen - Delayed Quote DKK

Gudme Raaschou European High Yield (GRIEHY.CO)

113.25 0.00 (0.00%)

At close: November 9 at 1:34:07 PM GMT+1

Loading Chart for GRIEHY.CO

Chart Range Bar

Interval:

In partnership with ChartIQ

PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.

PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.

PepGen Stock Doubles in One Session - Here's Why

PepGen Stock Doubles in One Session - Here's Why

INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 2026

INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 2026

How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis

How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis

Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity

Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity

Former Novartis CEO on What AI Can’t Replace in the Workplace

Former Novartis CEO on What AI Can’t Replace in the Workplace

IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch

IMVIONIX Acquires U.S. and Canadian Rights to BEOVU® (brolucizumab-dbll), Marking the Company's Official Launch

Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN

Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN

Exmar (ENXTBR:EXM) Stock May Be Fully Valued On Steady Cash Flow Assumptions

Exmar (ENXTBR:EXM) Stock May Be Fully Valued On Steady Cash Flow Assumptions

Novartis ranks first place in 2026 Access to Medicine Index

Novartis ranks first place in 2026 Access to Medicine Index

Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer

Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer

Mobilize your Website

View Site in Mobile | Classic

Share by: